---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-022214"
form_type: "8-K"
ticker: "NVNO"
cik: "0001661053"
company_name: "enVVeno Medical Corp"
filed_at: "2021-09-08T23:59:59+00:00"
generated_at: "2026-06-29T05:13:23.413387+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hancock Jaffe raises $20M in registered direct offering with Perceptive Advisors

## Summary
- Gross proceeds of $20M from sale of 781,615 shares at $7.872/share and pre-funded warrants for 1,759,035 shares at $0.0001 exercise.
- Net proceeds approximately $18.2M after placement agent fees (8% cash fee plus warrants) and expenses.
- Proceeds to be used for general corporate purposes and clinical development of the VenoValve.
- Company prohibited from issuing common stock or equivalents for 50 days post-closing; variable rate transactions banned for 6 months.
- Closing expected on or about September 9, 2021; Ladenburg Thalmann acting as exclusive placement agent.

## SEC filing metadata
- accession: 0001493152-21-022214
- form_type: 8-K
- ticker: NVNO
- cik: 0001661053
- company_name: enVVeno Medical Corp
- filed_at: 2021-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661053/000149315221022214/0001493152-21-022214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661053/000149315221022214/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-022214
- JSON: https://secwatch.observer/filing/0001493152-21-022214.json
- Plain text: https://secwatch.observer/filing/0001493152-21-022214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.